LAS
VEGAS, April 13, 2023 /PRNewswire/ -- JanOne
(Nasdaq: JAN), Dr. Amol Soin, Chief
Medical Officer of JanOne, will be presenting at the Appalachian
Region Spine and Pain Meeting in Sulfur Springs, West Virginia on Saturday, April 15th on the topic of
Innovation in Pain Medicine and will be discussing the drug
development programs at JanOne. JanOne is a biotech company that is
developing two different late-stage non-opioid drug candidates: JAN
101 is designed to treat peripheral artery disease that was also
shown to improve pain in patients with diabetic neuropathy in a
phase II study and JAN 123 which is low dose naltrexone to treat
Complex Regional Pain Syndrome. JAN 123 was granted orphan drug
status by the FDA.
"I look forward to presenting our research programs and drug
candidates from JanOne which I hope will provide two new non opioid
based pain medications to treat complex regional pain syndrome and
potentially pain from peripheral artery disease", noted Dr
Amol Soin.
The Appalachian Spine and Pain Meeting is a forum attended
mostly by pain management physicians to learn and discuss new and
innovative treatments. JanOne is working to develop multiple
medications to help treat pain without addiction. "The opioid
crisis really impacted this country and we realized what is needed
are new options to treat pain without opioids. We look forward to
developing these products so doctors have the tools they need to
treat pain without addiction", noted Tony Isaac CEO of JanOne.
"Pain physicians have been actively searching for new non-opioid
medications to treat chronic pain. The scientific discussions I
will have at this meeting will help to solidify our development
plans and will hopefully soon bring relief to patients." said Dr
Amol Soin.
Forward Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the statements that JAN 101 will treat PAD, that JAN
123 will treat CRPS, the timing of the commencement of further
clinical trials, that the FDA will permit approval through a
505(b)(2) pathway for JAN 123, that upon approval JAN 101 will
immediately disrupt the PAD market, and other statements, including
words such as "continue", "expect", "intend", "will", "hope"
"should", "would", "may", "potential" and other similar
expressions. Such statements reflect JanOne's current view with
respect to future events, are subject to risks and uncertainties,
and are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by JanOne, are
inherently subject to significant business, economic, competitive,
political and social uncertainties and contingencies. Many factors
could cause JanOne's actual results, performance or achievements to
be materially different from any future results, performance or
achievements described in this press release. Such factors could
include, among others, those detailed in the Company's periodic
reports filed with the Securities and Exchange Commission (the
"SEC").
Should one or more of these risks or uncertainties materialize,
or should the assumptions set out in the section entitled "Risk
Factors" in JanOne's filings with the SEC underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and JanOne
does not intend, and does not assume any obligation, to update
these forward-looking statements, except as required by law. JanOne
cannot assure that such statements will prove to be accurate as
actual results and future events could differ materially from those
anticipated in such statements. Individuals are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein.
About JanOne Inc.
JanOne is a unique Nasdaq-listed company offering innovative,
actionable solutions that it believes can help end the opioid
crisis. JanOne is dedicated to funding resources toward innovation,
technology and education to find a key resolution to the national
opioid epidemic, which is one of the deadliest and most widespread
in the nation's history. Its drugs in the clinical trial pipeline
have shown promise for their innovative targeting of the causes of
pain as a strategic option for physicians averse to exposing
patients to addictive opioids.
Please visit www.janone.com for additional information.
Media Contact
Investor Relations
IR@janone.com
1-800-400-2247
View original content to download
multimedia:https://www.prnewswire.com/news-releases/janone-to-present-data-on-its-two-non-opioid-drug-candidates-at-the-appalachian-region-spine-and-pain-meeting-on-drug-development-programs-to-treat-pain-on-april-15-2023-301796469.html
SOURCE JanOne Inc.